Survodutide

Dual glucagon receptor / GLP-1 receptor agonist peptide

ObesityMASH

Survodutide

Evidence levelLate-stage human

Human evidenceSubstantial

Regulatory statusInvestigational / not authorised

What you need to know in 20 seconds

What is it?	Dual glucagon receptor / GLP-1 receptor agonist peptide
Research focus	Obesity, MASH, liver fibrosis, cardiovascular outcomes
Human evidence	Randomized Phase 2 studies show dose-dependent weight loss in obesity and histologic MASH improvement without fibrosis worsening. Phase 3 development is ongoing.
Regulatory status	Investigational; no general marketing authorisation for obesity or MASH identified in the reviewed jurisdictions.
Main limitations	Long-term cardiovascular safety/benefit, durable MASH outcomes and routine-use dosing remain under Phase 3 investigation.
Safety	GI effects are common; long-term and rare-event safety is not yet established.

Randomized Phase 2 studies show dose-dependent weight loss in obesity and histologic MASH improvement without fibrosis worsening. Phase 3 development is ongoing.

What the evidence actually supports

✓Promising investigational obesity therapy; Phase 3 needed.
✓Separate MASH activity benefit from fibrosis claims.

What is not established / key limitations

×GI tolerability burden was high; no approved regimen or mature outcomes data yet.
×Fibrosis improvement was modest and not clearly dose-responsive; GI AEs frequent.

Selected study & evidence records

Survodutide for obesity: randomized Phase 2 dose-finding trial

2024 · Randomized, double-blind, placebo-controlled dose-finding trial · n=387

Mean weight changes were approximately -6.2%, -12.5%, -13.2% and -14.9% across ascending doses vs -2.8% placebo.

Study detail → Primary source ↗

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

2024 · Randomized, double-blind, placebo-controlled trial · n=293

Primary response 47%, 62%, 43% vs 14% placebo; ≥1-stage fibrosis improvement 34%, 36%, 34% vs 22%.

Study detail → Primary source ↗

Safety and unknowns

GI effects are common; long-term and rare-event safety is not yet established.

Nausea, diarrhoea and vomiting are frequent. In the Phase 2 MASH trial serious adverse events occurred in 8% on survodutide versus 7% on placebo.

Technical details

Mechanism / biologyDual glucagon and GLP-1 receptor agonism targets appetite, glycaemia, energy balance and hepatic metabolism.

Route / formulation boundaryEvidence is from trial-grade once-weekly subcutaneous product with protocol-driven escalation.

Identity / data-quality noteDo not conflate obesity and MASH trial regimens; doses and escalation differed.

Dosing evidence statusMultiple randomized Phase 2 regimens verified. Obesity dose-finding studied up to 4.8 mg weekly; MASH trial studied 2.4, 4.8 and 6.0 mg weekly with escalation.

Identifiers & alternate namesBI 456906 · BI456906